The global behcet’s disease drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Behcet's disease is also called Behcet's syndrome. It is a rare disorder that causes blood vessel inflammation throughout the body and can lead to numerous signs and symptoms such as mouth sores, eye inflammation, skin rashes and lesions, and genital sores. The major factor driving the market growth include the increasing prevalence of the behcet’s disease across the globe. 

According to the Vasculitis Foundation, Behcet’s mostly affects people in their 20s and 30s, however, it can occur in individuals of all ages. Additionally, Behcet’s occurs in both men and women, however, the males are at high risk. Furthermore, people from the Mediterranean, the Middle East and Asia are more likely to get this disease, however, it is rare in the US. Moreover, the prevalence of the syndrome is estimated at 3 to 5 per 100,000 people in the US. Apart from this, Turkey has the highest prevalence with approximately 400 cases per 100,000 people. Hence, the increasing prevalence of the disease is driving the demand for the drugs, which in turn, is driving the growth of the market.

Some major players operating in the market include Novartis International AG, Amgen Inc., and AbbVie Inc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2019, Celgene Corp. announced the approval of OTEZLA (apremilast) from the US Food and Drug Administration (FDA). It is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) taken twice daily for the treatment of adult patients with oral ulcers associated with Behcet’s Disease.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Route of Administration

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Novartis International AG, Amgen Inc., and AbbVie Inc, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Behcet’s Disease Drug Market Report by Segment

By Type

• Corticosteroids
• Adalimumab Biosimilar
• Infliximab Biosimilar
• Apremilast
• Canakinumab
• Others

By Route of Administration

• Oral
• Intravenous
• Intramuscular
• Topical
• Others

Global Behcet’s Disease Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa